Mertansine is a tubulin inhibitor and an antibody-conjugable maytansinoid alkaloid. The IC50 of Mertansine against HCT-15 and A431 cells is 0.750 and 0.04nM.

UGT1A1:856.7 nM, CYP2B6:36.8 nM, UGT1A9:54.1 nM, CYP2C8:32.1 nM, CYP2C19:539.5 nM, CYP3A4:160.6 nM, CYP1A2:93.7 nM

METHODS: HCT-15 and A431 cells were incubated with Mertansine (0-3 nM) for 72 hours, then the medium was removed from the plate and replaced with fresh medium. Allow the culture to grow and form colonies for 7-10 days after plating. Cultures were fixed, stained with 0.2% crystal violet in 10% formalin/PBS, and colonies were counted. RESULTS Mertansine can inhibit the growth of HCT-15 and A431 cells. [1]
METHODS: 4T1 cells were incubated with Mertansine (5-100 μg/mL) for 4 hours, and cell viability was detected by CCk8.
RESULTS Mertansine can inhibit the growth of 4T1 cells.[2]
METHODS: MDA-MB-231 cells were incubated with Mertansine (0.001355–13.55μM) for 48 hours, and cancer cell viability was detected by MTT.
RESULTS Mertansine can effectively inhibit the proliferation of MDA-MB-231 cells, with an IC50 value of 0.12 μM. [3]

METHODS: The anti-tumor activity of Mertansine (0.5 mg/kg) was evaluated in mice with orthotopic 4T1 tumors. RESULTS Cancer cell apoptosis was significantly increased, and the effect was dose-dependent. [2] METHODS: The in vivo therapeutic properties of Mertansine were evaluated using MDA-MB-231 triple-negative breast tumor mice. Mertansine was administered every 3 days for a total of four injections at a dose of 0.8 mg/kg. RESULTS Mertansine demonstrated modest inhibition of cancer cell growth in MDA-MB-231 triple-negative mammary tumor mice.[3]